glp 1 parkinson's The glucagon-like peptide (GLP) receptor as a therapeutic target in disease: mechanisms of action GLP-1 Receptor Agonists in Neurodegeneration:

Because postmenopausal women on hormone therapy combined with GLP-1s often achieve significantly greater weight loss than those on GLP-1s alone, AI models could track symptoms alongside metabolic markers and help determine the optimal dosage of the GLP-1 to use in conjunction with hormone therapy, maximizing the benefit of both

The bullish case rests on its potential to capture market share

The recommended maximal daily dose of gabapentin is 1,500 mg in people with grade 3 chronic kidney disease (CKD), 700 mg in those with grade 4 CKD, 300 mg in those with grade 5 CKD, and 100 to 300 mg after dialysis in dialysis patients

10.1186/s12958-023-01147-w 71 GuptaV